PA
Paradigm Biopharmaceuticals Limited
PAR.AX · ASX
$0.27 -1.82% (-$0.01)
1M +57.14%
Market Cap $164.8M
P/E Ratio -
Div. Yield -
ROE 348.22%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/B 47.48x
P/S 2,055.86x
EV/EBITDA N/A
Growth
78 /100
Growing Book val. growth 59.86%
Rev. growth 19.68%
FCF growth N/A
Profitability
0 /100
Weak Net margin 70,282.30%
Op. margin 76,246.50%
FCF margin 54,506.00%
Quality
0 /100
Poor ROE 348.22%
ROA 184.36%
Asset turnover 0.00x
Debt
17 /100
High Current ratio 1.10x
Int. coverage -24.83x
Debt/Equity 2.16x
Stability
15 /100
Unstable Rev. volatility 39.82%
EPS volatility 112.00%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PAR.AX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Paul John Rennie
Employees
12
Headquarters
Melbourne
Prihajajoči dogodki
24 FEB.
Earnings
Upcoming earnings report